Skip to main content

Search articles in Clinical Research

Found 248 articles

  • Voydeya approved in the US as add-on therapy to ra

    Voydeya approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular haemolysis in adults with the rare disease PNH

    • 2 Apr 2024
    • Editor

    Voydeya (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular haemolysis (EVH) in adults with paroxysmal nocturnal haemoglobinuria (PNH).1

  • Datopotamab deruxtecan Biologics License Applicati

    Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer

    • 2 Apr 2024
    • Editor

    AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior systemic therapy for unresectable or metastatic disease.

  • Moderna Advances Multiple Vaccine Programs to Late

    Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

    • 2 Apr 2024
    • Editor

    Moderna, Inc. (NASDAQ:MRNA) today announced at its fifth Vaccines Day event clinical and program updates demonstrating advancement and acceleration of its mRNA pipeline. The updates include data readouts in the Company's respiratory and latent and other vaccine portfolios, as well as commercial, manufacturing and financial announcements for its vaccines business.

  • Caidya Expands Global Presence with the Establishm

    Caidya Expands Global Presence with the Establishment of Caidya Canada Limited and New Office in Toronto

    • 2 Apr 2024
    • Editor

    Caidya, a leading global, multi-therapeutic clinical research organization (CRO), is pleased to announce the establishment of its new legal entity, Caidya Canada Limited, and the opening of its new office in Toronto, Ontario.

  • Takeda Announces Positive Topline Results from Pha

    Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

    • 14 Mar 2024
    • Editor

    Takeda (TSE:4502/NYSE:TAK) today announced positive topline results from a Phase 2, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP).

  • What do Clinical Research Organisations Do?

    What do Clinical Research Organisations Do?

    • 13 Mar 2024
    • Lucy Walters

    Clinical Research Organisations (CROs) play a crucial role in advancing medical knowledge and therapeutic innovations. As vital intermediaries between pharmaceutical and biotechnology companies, healthcare professionals, and regulatory bodies, CROs help facilitate the clinical development of new drugs, devices, and treatments.

  • Merck Announces Plans to Conduct Clinical Trials o

    Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL ® 9

    • 13 Mar 2024
    • Editor

    Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today, at the EUROGIN 2024 HPV Congress, announced plans to initiate clinical development of a new investigational multi-valent HPV vaccine designed to provide broader protection against multiple HPV types.

  • New Data to be Presented for BioMarin's VOXZOGO® (

    New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

    • 13 Mar 2024
    • Editor

    BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that positive early results from an investigator-sponsored Phase 2 study of VOXZOGO® (vosoritide) in children with hypochondroplasia, will be presented at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Toronto, Canada, March 12-16, 2024.

  • 6 Clinical Research Associate Interview Tips: How

    6 Clinical Research Associate Interview Tips: How to Make a Great Impression

    • 12 Mar 2024
    • Editor

    Your job interview is the perfect opportunity to make a lasting impression on a potential employer. Everything you do before, during, and after your job interview can significantly impact your interviewer’s perception of you.

  • More than two-thirds of people with atopic dermati

    More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study

    • 11 Mar 2024
    • Editor

    Eli Lilly and Company (NYSE: LLY) announced results from a first-of-its-kind study of lebrikizumab specifically designed for people with skin of color and moderate-to-severe atopic dermatitis, commonly called eczema.

  • New Phase 2b results for amlitelimab support poten

    New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis

    • 11 Mar 2024
    • Editor

    Positive results from Part 2 of the investigational amlitelimab Phase 2b study STREAM-AD showed sustained improvement of signs and symptoms for 28 weeks in adults with moderate to severe AD who previously responded to amlitelimab and continued treatment.

  • GSK announces positive results from DREAMM-8 phase

    GSK announces positive results from DREAMM-8 phase III trial for Blenrep versus standard of care combination in relapsed/refractory multiple myeloma

    • 8 Mar 2024
    • Editor

    GSK plc (LSE/NYSE: GSK) today announced positive headline results from an interim analysis of the DREAMM-8 phase III head-to-head trial evaluating Blenrep (belantamab mafodotin), in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, bortezomib plus PomDex, as a second line and later treatment for relapsed or refractory multiple myeloma.

  • Average UK Clinical Research Salaries in 2024

    Average UK Clinical Research Salaries in 2024

    • 7 Mar 2024
    • Lucy Walters

    The UK government is currently on a mission to make the UK one of the best places in the world to conduct clinical trials. Throughout 2024 and 2025, the government will be implementing recommendations made by Lord O’Shaughnessy in his 2023 independent review of UK commercial clinical trials to make this happen.

  • Transgene, NEC and BostonGene Expand Collaboration

    Transgene, NEC and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050

    • 6 Mar 2024
    • Editor

    Transgene, NEC Corporation, and BostonGene Corporation (BostonGene), a leading company in AI-based molecular and immune profiling, today announced the expansion of their collaboration for the randomized Phase I/II trial of TG4050, an individualized therapeutic vaccine for patients with head and neck cancers.

  • Top 9 Clinical Research Organisations in 2024

    Top 9 Clinical Research Organisations in 2024

    • 6 Mar 2024
    • Lucy Walters

    In terms of revenue, the global clinical trials market was estimated to be worth $48.2 billion in 2023 and is expected to reach $73.2 billion by 2028, growing at a CAGR of 8.7%. In this article, we’ve rounded up 9 of the top Clinical Research Organisations (CROs) in the world, highlighting the key drivers of this growth.

  • Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates

    Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial

    • 6 Mar 2024
    • Editor

    Novo Nordisk today announced the headline results from the kidney outcomes trial FLOW. The announcement today follows the decision to stop the trial early due to efficacy, which was announced on 10 October 2023, based on a recommendation from an Independent Data Monitoring Committee.

  • Roche and Alnylam report positive topline results

    Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care

    • 6 Mar 2024
    • Editor

    Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam announced today that the Phase II KARDIA-2 study [NCT05103332] of zilebesiran, an investigational RNAi therapeutic in development for the treatment of hypertension (high blood pressure) - the leading cause of cardiovascular disease worldwide1 - met its primary endpoint.

  • Immutep Announces First Clinical Data from 90mg Do

    Immutep Announces First Clinical Data from 90mg Dosing of Efti

    • 6 Mar 2024
    • Editor

    Immutep (Formerly known as Prima Biomed) Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces safety and initial efficacy data from the first ever 90mg dosing of eftilagimod alpha (efti) in combination with weekly paclitaxel in patients from the safety lead-in (N=6) of the AIPAC-003 Phase II/III trial.

  • 5 Clinical Research Recruitment Trends for 2024

    5 Clinical Research Recruitment Trends for 2024

    • 5 Mar 2024
    • Lucy Walters

    The global clinical trials market size was valued at USD 80.7 billion in 2023 and is projected to grow at a CAGR of 6.49% from 2024 to 2030. Despite this anticipated growth, the clinical research industry has faced huge challenges over the past year, largely driven by political and economic turbulence.

  • PharmAust announces positive Phase 1 MEND Study To

    PharmAust announces positive Phase 1 MEND Study Top-Line Results in MND / ALS

    • 29 Feb 2024
    • Editor

    PharmAust Limited (ASX: PAA & PAAOA) ("PharmAust" or "the Company"), a clinical-stage biotechnology company, is pleased to announce that it has met its primary safety and tolerability endpoints with monepantel (MPL) and, importantly, demonstrated a positive signal of potential efficacy.